March 1, 2022
Shionogi and Ube Industries said on February 28 they have sealed a strategic collaboration to jointly develop S-337395, a novel anti-respiratory syncytial virus (RSV) drug candidate, aiming to bring it into the clinic in FY2023, which will end in March...read more